source
- FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel oppositionFDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients. The approval was issued on Friday even th…
- AbbVie’s etentamig shows strong survival and response gains in Phase 3 multiple myeloma trialAbbVie reported that its investigational bispecific T‑cell engager, etentamig, significantly reduced the risk of disease progression or death in a Phase 3 study of patients with relapsed or refract…